PATH vs SLRX
Uipath Inc (PATH) versus Salarius Pharmaceuticals Inc (SLRX) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Salarius Pharmaceuticals Inc (SLRX) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SLRX revenue for 2023-03-31 was $0. Net income was -$5.3M. SLRX currently screens at market cap $4.9M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SLRX currently screens at market cap $4.9M.
Not investment advice. Open the PATH and SLRX stock pages for the full models.
Not investment advice.